Ann: First Patient Dosed in VAXINIA Intravenous Cohort 2, page-11

"Once patients in the monotherapy group have been treated with the lowest doses of VAXINIA and acceptable safety has been demonstrated, new study participants will receive combination treatment, CF33-hNIS with the immunotherapy pembrolizumab. This is expected to begin following cohort 2 being cleared per route of administration. Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia."

I am bit confused with the above 'bold' bit of the announcement. I thought convention is to finish PH1 to determine optimal dose and safety of Vaxinia. And then proceed with whatever combo plan. But here, it seems like after this Cohort 2 is done, new patients will go straight into combo with Keytruda.

Is that a hint that even with the very low dose Cohort 1, it should be good enough dose from what they seen? And that this Cohort 2 higher dose should be the optimal dose already if it is proven safe as well? Otherwise, surely they won't go into combo without knowledge of optimal dosage, right?